News

404

Immunophotonics Announces First Patient Dosed in Phase 2a Clinical Trial of IP-001 in advanced solid tumor indications

Immunophotonics Announces First Patient Dosed in Phase 2a Clinical Trial of IP-001 in advanced solid tumor indications

Immunophotonics announced that the first patient has been dosed in the phase 2a portion of its Swiss clinical trial for treatment of multiple selected cancer indications. This multicenter clinical trial is designed to evaluate the immunologically mediated anticancer effects of intratumorally injecting the company’s lead asset, IP-001, following thermal ablation in patients with advanced solid...

Immunophotonics HEC-TV Interview

Immunophotonics was interviewed by HEC-TV, St. Louis on our lead asset IP-001. Immunophotonics would not be where they are today if it weren’t for the entire team, many of whom are featured in this segment. Great Job Abby Delawder, Chun Fung (Johnny) Wong, Siu Kit (Samuel) Lam, Lu Alleruzzo, Tomas Hode. To View Click Here

Swiss Biotech Day May 2-3, 2022

The Immunophotonics Team is thrilled to announce that Dr. Theresa Visarius of Immunophotonics Switzerland (IPS Biopharma) will be presenting at the Swiss Biotech Day on Tuesday, May 3rd in the Clinical Stage Development Company category.

US Oncology Research BioTech Day, Early Development Program Summit

Samuel Lam, PhD, Vice President of Science and Research at Immunophotonics, Inc. and Markus Joerger, MD, PhD, Clinical Trial Principal Investigator spoke at the US Oncology Research BioTech Day, Early Development Program (EDP) Summit in Coronado, California, on April 27, 2022 at 1:00 p.m. in the Glorietta Room. Immunophotonics thanks Dr. Dan Von Hoff and...

European Conference on Interventional Oncology (EICO 2022) April 24–27, 2022

Interested in learning how Immunophotonics, Inc. continues to explore the ability of IP-001 to transform a routine interventional-oncology procedure into a systemic immunotherapy against cancer. Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. will be attending the European Conference on Interventional Oncology (EICO 2022) in Vienna, Austria April 24 – 27, 2022. This...

SIO Annual Scientific Meeting, March 24 -28, 2022

Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. attended the SIO 2022 annual scientific meeting March 24 – 28 in San Francisco, California. He connected with interventional oncology professionals and learned about the developments in cancer therapy worldwide alongside medical, surgical and radiation oncology.

Dr. Wei R. Chen Elected to the 2022 Class of the AIMBE College of Fellows

Lu Alleruzzo, CEO; Tomas Hode, CIO & President; and the Immunophotonics Team want to congratulate Dr. Wei Chen on being elected to the American Institute of Medical and Biological Engineering (AIMBE) College of Fellows for his outstanding contributions to the invention, development, translation, and commercialization of laser immunotherapy for the treatment of metastatic cancers. This...

2022 St. Louis Dealmaker of the Year

The continued success of Immunophotonics is driven by the dedication and hard work of our team. Immunophotonics was one of 11 dealmakers honored on March 4th at the 2022 St. Louis Dealmakers Conference. Smart Business Dealmakers was created by the Smart Business Dealmakers Institute to serve as a resource for news, insights, and networking for...

Immunophotonics Awarded $2.4 Million SBIR Grant by the National Cancer Institute

Immunophotonics, Inc. was recently awarded a Small Business Innovative Research (SBIR) Phase I and Phase II Fast-Track grant for research regarding use of the company’s lead drug candidate, IP-001 by the NIH’s National Cancer Institute. This research will be conducted by Immunophotonics Inc and its collaborators at the University of Louisville Division of Surgical Oncology....

Scroll to top